Compare · ANIP vs AZN
ANIP vs AZN
Side-by-side comparison of ANI Pharmaceuticals Inc. (ANIP) and AstraZeneca PLC (AZN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANIP and AZN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $547.19B, about 302.4x ANIP ($1.81B).
- Over the past year, ANIP is up 25.6% and AZN is down 3.9% - ANIP leads by 29.5 points.
- AZN has been more active in the news (9 items in the past 4 weeks vs 7 for ANIP).
- AZN has more recent analyst coverage (25 ratings vs 11 for ANIP).
- Company
- ANI Pharmaceuticals Inc.
- AstraZeneca PLC
- Price
- $82.90+2.92%
- $180.98+2.60%
- Market cap
- $1.81B
- $547.19B
- 1M return
- +0.27%
- -4.64%
- 1Y return
- +25.63%
- -3.88%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 7
- 9
- Recent ratings
- 11
- 25
ANI Pharmaceuticals Inc.
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest ANIP
- SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $41,015 worth of shares (500 units at $82.03) as part of a pre-agreed trading plan, decreasing direct ownership by 0.64% to 77,890 units (SEC Form 4)
- Director Thoma Jeanne was granted 4,357 shares, increasing direct ownership by 19% to 27,762 units (SEC Form 4)
- Director Tannenbaum Renee P was granted 4,357 shares, increasing direct ownership by 17% to 29,514 units (SEC Form 4)
- Director Pera Antonio R was granted 4,357 shares, increasing direct ownership by 19% to 27,017 units (SEC Form 4)
- Director Leonard Matthew J was granted 4,357 shares, increasing direct ownership by 63% to 11,221 units (SEC Form 4)
- Director Haughey Thomas was granted 4,357 shares and sold $161,760 worth of shares (2,000 units at $80.88) as part of a pre-agreed trading plan, increasing direct ownership by 6% to 38,878 units (SEC Form 4)
- SVP & CFO Carey Stephen P. exercised 3,312 shares at a strike of $49.51 and sold $264,960 worth of shares (3,312 units at $80.00) as part of a pre-agreed trading plan (SEC Form 4)
- ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
- ANI Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Walsh Patrick D sold $1,127,120 worth of shares (13,973 units at $80.66), decreasing direct ownership by 27% to 38,432 units (SEC Form 4)
Latest AZN
- Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
- Officer Sharma Mani was granted 1 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,263 units (SEC Form 4)
- SEC Form 6-K filed by AstraZeneca PLC
- TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
- NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC